Response Predictive Subtypes in Lobular Tumors-FLEX, Mukhtar et al., SABCS 2023 Abstract
SABCS 2023, PO4-02-03 Authors: Mukhtar et al.
Read MoreMINDACT & TAILORx Exploratory Comparison, Neven et al., SABCS 2023 Abstract
SABCS 2023, PO1-02-05 Authors: Patrick Neven et al.
Read MoreFLEX Study Update, Alberty et al, SABCS 2023 Abstract
SABCS 2023, PO3-02-02 Authors: JJ Alberty-Oller, et al.
Read MoreComparison of genomic test scores and CT Indications – SABCS 2023
SABCS 2023 Author: Vidal, Singh et al.
Read MoreNurse Navigatorsโ Role in Personalized ESBC Treatment, A Case Study
Publication: Journal of Oncology Navigation & Survivorship, Nov 2023, Vol 14 Authors: Jo Weathers, RN, BSN, OCN, ONN-CG; Jane Baker, RN, MSN; Victoria Poillucci, DNP, MEd, ACNP-BC; Christina Z. Page, AOCNP, AGPCNP-BC
Read MoreThe Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
Publication: Annals of Surgical Oncology, Sept 1 2023 Authors: Peter Blumencranz MD, FACS, Mehran Habibi MD, Steve Shivers PhD, Geza Acs MD, Lisa E. Blumencranz PhD, Erin B. Yoder MS, Bastiaan van der Baan MS, Andrea R. Menicucci PhD, Patricia Dauer PhD, William Audeh MD & Charles E. Cox MD
Read MoreTRAIN 2 Trial: BluePrint predicts response to neoadjuvant pertuzumab in HER2-positive
Breast Cancer Research 25, Article Number: 71 (2023) Authors: Liefaard et al.
Read MoreMammaPrintยฎ Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2 breast cancer in NBRST
Publication: ASCO 2023, Abstract #521 Authors: Peter D. Beitsch 1 , James V. Pellicane 2 , Lajos Pusztai 3 , Paul L. Baron 4 , Erin F. Cobain 5 , Mary K. Murray 6 , Andrew Ashikari 7 , Pond R. Kelemen 7 , Angela Marie Mislowsky 8 , Julie Barone 9 , Kenneth H. Cowan 10 , Rakhshanda Layeequr Rahman 11 , William C. Dooley 12 , Andrea Menicucci 13 , Christine Carruth 13 , M. William Audeh 13 , Pat W. Whitworth 14 , NBRST Investigators Group
Read MoreFLEX: 30K Full Transcriptome, Real-World Evidence Database for Early-Stage Breast Cancer, and Investigator-Initiated Protocols
Publication: ASCO 2023, Abstract #TPS621 Authors: Eric A. Brown1; Linsey P. Gold1; Carl R. Gray2; Douglas K. Marks3; Vibha T. Thomas4; Alfredo A. Santillan5; Cynthia Ma6; Ciera Singleton7; William Audeh7; on behalf of the FLEX Investigators Group 1. Comprehensive Breast Care, Troy, MI; 2. Utah Hem Onc, Ogden, UT; 3. Perlmutter Cancer Center, NYU Langone Health, New York, NY; 4. Texas Oncology-Flower Mound, Flower Mound, TX; 5. Texas Oncology PA, San Antonio, TX; 6. Washington University School of Medicine, St. Louis, MO; 7. Agendia Inc., Irvine, CA.
Read MoreImpact of race on BluePrint genomic subtyping in HER2+ breast cancer
Publication: ASCO 2023, Abstract #TPS621 Authors: Eric A. Brown1; Linsey P. Gold1; Carl R. Gray2; Douglas K. Marks3; Vibha T. Thomas4; Alfredo A. Santillan5; Cynthia Ma6; Ciera Singleton7; William Audeh7; on behalf of the FLEX Investigators Group 1. Comprehensive Breast Care, Troy, MI; 2. Utah Hem Onc, Ogden, UT; 3. Perlmutter Cancer Center, NYU Langone Health, New York, NY; 4. Texas Oncology-Flower Mound, Flower Mound, TX; 5. Texas Oncology PA, San Antonio, TX; 6. Washington University School of Medicine, St. Louis, MO; 7. Agendia Inc., Irvine, CA.
Read More
